B-IFX demonstrated comparable real-world effectiveness and safety to O-IFX while generating substantial cost savings for China's medical insurance system. These findings support broader biosimilar adoption as a value-based strategy to enhance the affordability and sustainability of biologic therapy for CD.
Shi et al. (Tue,) studied this question.